AzTrials
AzTrials

Greater Trochanteric Pain SyndromeHILT-GTPSNCT07749066

HILT in Greater Trochanteric Pain Syndrome

A study testing High-Intensity Laser Therapy (HILT) in people with Greater Trochanteric Pain Syndrome, run by Ankara Etlik City Hospital at 1 site in Turkey (Türkiye).

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Greater Trochanteric Pain Syndrome (GTPS) is a common cause of lateral hip pain that can significantly impair daily activities and quality of life. Conservative treatments, including physical therapy modalities and injections, are considered first-line management. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Greater Trochanteric Pain Syndrome
What is being tested?
High-Intensity Laser Therapy (HILT)
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
64 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Jun 2026to 30 Jul 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults aged 18 to 80 years
  • Patients diagnosed with Greater Trochanteric Pain Syndrome (GTPS) based on clinical examination
  • Presence of symptoms for at least 3 months
  • Pain intensity ≥4 on the Visual Analog Scale (VAS)
  • No corticosteroid injection or other conservative treatment within the last 3 months

Who cannot join

  • Hip fracture, tumor, infection, or advanced osteoarthritis
  • Contraindications to high-intensity laser therapy (e.g., pacemaker, pregnancy, coagulation disorders, anticoagulant therapy, neoplasia, history of epilepsy)
  • Contraindications to physical activity (e.g., ischemic heart disease, arrhythmia, uncontrolled hypertension, heart failure, severe respiratory insufficiency)
  • Peripheral vascular disorders (e.g., thrombophlebitis, thrombosis, lymphedema)
  • History of trauma within the last 3 months or prior surgery involving the lower extremity or lumbar spine
  • Neurological disorders or chronic inflammatory diseases

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Gizem Suna Tuncer, MD, Specialist Physician contact

+905347953185

sunagizem05@gmail.com

Turkey (Türkiye)1 site, 1 recruiting
  • Etlik City Hospital

    Ankara, Yenimahalle, 06370

    Gizem Suna Tuncer, +905347953185, sunagizem05@gmail.com

    Recruiting

Other trials in Turkey (Türkiye)

About this study

Official title: Efficacy of High-Intensity Laser Therapy in Greater Trochanteric Pain Syndrome: A Randomized Controlled Trial

Greater Trochanteric Pain Syndrome (GTPS) is a common cause of lateral hip pain that can significantly impair daily activities and quality of life. Conservative treatments, including physical therapy modalities and injections, are considered first-line management.

High-Intensity Laser Therapy (HILT) is a non-invasive modality with greater tissue penetration compared to low-level laser therapy and has shown promising results in musculoskeletal disorders; however, evidence in GTPS is limited.

This study aims to evaluate the efficacy of HILT compared with a sham intervention in patients with GTPS, focusing on pain intensity, functional status, and quality of life.

Being tested
High-Intensity Laser Therapy (HILT), Sham Laser
Keywords
Greater Trochanteric Pain Syndrome, GTPS, High-Intensity Laser Therapy, HILT, Lateral Hip Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • High-Intensity Laser Therapy (HILT)Device

    High-intensity laser therapy will be applied to the trochanteric region using a pulsed Nd:YAG laser device over 10 sessions (5 sessions per week for 2 consecutive weeks). Treatments will be delivered by an experienced physiotherapist using a standardized protocol and consistent application technique. Total energy per session will be standardized. Participants will also perform a structured home exercise program focusing on hip muscle activation and flexibility.

  • Sham LaserDevice

    A sham laser intervention will be applied using the same device and treatment setup without delivering therapeutic laser energy. The number and frequency of sessions will be identical to the active treatment group to ensure blinding. Participants will also perform the same structured home exercise program as the intervention group.

Study groups in NCT07749066
Study groupRoleWhat they receive
High-Intensity Laser Therapy (HILT) + ExerciseActive comparatorParticipants will receive high-intensity laser therapy (HILT) in addition to a standardized home exercise program. The exercise program will include hip strengthening, stretching, and movement control exercises targeting the gluteal muscles and peri-trochanteric soft tissues. HILT will be applied to the greater trochanteric region over 10 treatment sessions (5 sessions per week for 2 consecutive weeks) using a standardized treatment protocol.
Receives: Device: High-Intensity Laser Therapy (HILT)
Sham Laser + Exercise (Control Group)Sham comparatorParticipants will receive the same standardized home exercise program as the intervention group. In addition, a sham laser treatment will be applied using the same device and treatment setup without delivering therapeutic laser energy. The number and frequency of sessions will be identical to the active treatment group to ensure blinding.
Receives: Device: Sham Laser

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain Intensity (Visual Analog Scale, VAS)

    Pain intensity will be assessed using a 0-10 Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates worst imaginable pain.

    Measured: Baseline (T0), 2 weeks (end of the treatment period; T1), and 8 weeks after treatment completion (T2).

Secondary outcomes (4)
  1. Pressure Pain Threshold (Algometry)

    Pressure pain threshold will be measured using a digital algometer at the most tender point over the greater trochanter. Measurements will be performed in lateral decubitus position with perpendicular probe application, increasing pressure at approximately 1 kg/s until the first sensation of pain is reported. Three measurements will be taken at 30-second intervals, and the average value (kg/cm²) will be used for analysis. All measurements will be performed by the same assessor.

    Measured: Baseline (T0), 2 weeks (end of the treatment period; T1), and 8 weeks after treatment completion (T2).

  2. Lower Extremity Functional Scale (LEFS)

    The LEFS is a patient-reported outcome measure assessing difficulty in performing 20 daily activities. Each item is scored from 0 (extreme difficulty or unable to perform) to 4 (no difficulty), with a total score ranging from 0 to 80, where higher scores indicate better function.

    Measured: Baseline (T0), 2 weeks (end of the treatment period; T1), and 8 weeks after treatment completion (T2).

  3. Roles and Maudsley Score (RMS)

    The Roles and Maudsley Score is a 4-point categorical scale evaluating patient-perceived recovery, ranging from 1 (excellent) to 4 (poor or unchanged symptoms).

    Measured: 2 weeks (end of the treatment period; T1), and 8 weeks after treatment completion (T2).

  4. Single-Leg Stance Test

    The single-leg stance test assesses balance and hip abductor function. Participants stand on one leg with arms relaxed at the sides, maintaining an upright posture. The duration (in seconds) is recorded up to a maximum of 30 seconds. The test is terminated if balance is lost, the non-stance foot touches the ground, or compensatory movements occur.

    Measured: Baseline (T0), 2 weeks (end of the treatment period; T1), and 8 weeks after treatment completion (T2).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Aug 2026
  2. Study start1 Jun 2026
  3. Primary completion30 Jun 2027 (estimated)
  4. Study completion30 Jul 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a randomized, double-blind, sham-controlled, parallel-group study in which patients with GTPS are allocated to HILT or sham treatment, with outcomes assessed at baseline, post-treatment, and follow-up.
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
64 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07749066
Sponsor's protocol ID
AESH-EK-2026-064
Acronym
HILT-GTPS
Status last verified
Jul 2026
First submitted
19 Jul 2026
Last updated
6 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing High-Intensity Laser Therapy (HILT) in people with Greater Trochanteric Pain Syndrome, run by Ankara Etlik City Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Gizem Suna Tuncer, MD, Specialist Physician (+905347953185, sunagizem05@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain Intensity (Visual Analog Scale, VAS) (time frame: Baseline (T0), 2 weeks (end of the treatment period; T1), and 8 weeks after treatment completion (T2).). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in